Royalty Report: Delivery, Medical, Device – Collection: 26581

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Delivery
  • Medical
  • Device
  • Drugs
  • Therapeutic
  • Respiratory
  • Pharmaceuticals
  • Diagnostic
  • cardiac
  • Cancer
  • Disease
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26581

License Grant
The Licensor hereby grants to a Denmark Company a world-wide, exclusive, royalty-bearing license under the Aradigm Patent Rights (including applicable Aradigm Background IPR), Aradigm Selected Pulmonary Delivery Patent Rights, Aradigm New IPR and Aradigm Know-How (including applicable Aradigm Background IPR) to (a) develop, manufacture, use, market, distribute, sell, offer for sale, have made, import and/or export any Packaged Product and the Device in and from the Territory for use within the Field, with the right to sublicense its customers and Joint Marketing Partners pursuant and (b) otherwise exercise and perform its rights and obligations under this Agreement.
License Property
AERx iDMS insulin diabetes management system (iDMS uses a unique liquid human insulin strip to deliver an aerosol of insulin to the lungs. AERx iDMS enables 1-unit increment dosing, and the device ensures that the insulin dose is released at the optimal point of inhalation for delivery to the lungs.  The device was used for dosing fast-acting human insulin immediately before main meals, in combination with bedtime NPH insulin. The AERx iDMS device recorded the date and time of each insulin inhalation, insulin units used, and inhalation technique during aerosol delivery.

The AERx iDMS is being designed as a painless and convenient alternative to insulin injection. This should enable patients with diabetes to comply more effectively with their insulin therapy, thereby reducing the risk of long-term complications.  AERx iDMS is being developed to control blood glucose levels in patients with diabetes.

Field of Use
Field shall mean pulmonary administration of insulin, insulin analogs and any other compounds whose principal therapeutic effect is to control blood glucose levels in humans, including but not limited to glucagon-like peptide (GLP), GLP-1 and analogs of GLP.

IPSCIO Record ID: 25862

License Grant
The Company executed a development and commercialization agreement with the Denmark Licensee to jointly develop a pulmonary delivery system for administering insulin by inhalation.

Under the terms of the agreement, Licensee has been granted exclusive rights to worldwide sales and marketing rights for any products developed under the terms of the agreement.

License Property
Through December 31, 2005, the Company received from Licensee $150.1 million in product development and milestone payments. Under the terms of the development agreement in effect at December 31, 2005 between the Company and Licensee, prior to completion of the restructuring transaction, Licensee was to fund all product development costs incurred by the Company under the terms of the agreement, and the Company was to be the initial manufacturer of the product and was to receive a share of the overall gross profits resulting from Licensee's sales of the product while Licensee and the Company agreed to co-fund final development of the AERx device.
Field of Use
The most advanced program using our AERx technology platform is AERx iDMS for the treatment of diabetes with inhaled insulin, asan alternative to injectable insulin, which is being developed by Novo Nordisk and is now in Phase 3 clinical trials. We have shown in the development program with AERx iDMS that the system is capable of delivering insulin into the blood streamfaster than by subcutaneous injection of regular insulin, thus providing a more convenient, patient-friendly approach to controlling meal-time glucose levels. Our patented breath control methods and technologies guide patients into the optimal breathing pattern for effective insulin deposition in and absorption from the lung. Pursuant to our agreement with Licensee, Licensee is responsible for and is funding all development, manufacturing and commercialization activities, and we will be entitled to receive a royalty on net sales.

IPSCIO Record ID: 28464

License Grant
The US Corporation grants a Denmark company a world-wide, exclusive, royalty-bearing license under the Patent Rights and Know-How to (a) develop, manufacture, use, market, distribute, sell, offer for sale, have made, import and/or export any Packaged Product and the Device in and from the Territory for use within the Field, with the right to sublicense its customers and Joint Marketing Partners and (b) otherwise exercise and perform its rights and obligations under this Agreement.

The US Corporation grants the Denmark company the right to sublicense its customers and Joint Marketing Partners, under the company's licenses under the Patent Rights and Know-How in this Agreement (as applicable) to (a) use any Packaged Product and the Device and (b) market, distribute, sell, offer to sell, import and/or export any Packaged Product and the Device, so long as said items were bought from any member of the Denmark company Affiliate Group or from a Joint Marketing Partner.

License Property
The original license agreement was to develop a system for pulmonary delivery of insulin (and potentially other compounds) and under which the US Corporation granted to the Denmark company an exclusive, world-wide license under certain patent rights and “know-how”, to use, market, distribute, sell and sublicense products resulting from such development program.
Field of Use
Field shall mean pulmonary administration of insulin, insulin analogs and any other compounds whose principal therapeutic effect is to control blood glucose levels in humans, including but not limited to glucagon-like peptide (“GLP”), GLP-1 and analogs of GLP.

IPSCIO Record ID: 286077

License Grant
Licensor grants an exclusive license for the Licensor Technology in the Territory to research, Develop, Commercialize, use, import, register, sell, have sold, and distribute Products in the Field within the Territory.

Licensor grants a non-exclusive license for the Licensor Technology in the Territory to make and have made Products in the Field in the Territory.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has certain proprietary rights related to a pulmonary drug delivery technology known as AERx® technology, as well as expertise and know-how relating to the use and manufacture of such technology.

The licensed Technology means, only if it relates to the AERx pulmonary drug delivery system and collectively, the Licensor Patents, Licensor Know-How, Licensor New Intellectual Property, all Information relating to the Licensor Patents, Know-How, and New Intellectual Property in the course of any work conducted pursuant to this Agreement, and Licensor Improvements.

The patents include, but are not limited to, Disposable package for intrapulmonary delivery of aerosolized formulations; Methos of fabricating porous membrane with unique pore structure for aerosolized delivery of drugs;  Aerosol-forming porous membrane with certain pore structure;  Device and method of creating aerosolized mist of respiratory drug; Lockout device for controlled release of drug from patient-activated dispenser; and, Method of administration of insulin.

Field of Use
Field means pulmonary delivery of prostacyclin drugs for the treatment of pulmonary arterial hypertension and any and all other therapeutic indications and uses other than control of glucose levels in humans.

IPSCIO Record ID: 1804

License Grant
The Company hereby grants the worldwide right to manufacture, cause to be manufactured, promote, sell, market, distribute and use the Pump Technology; programmable implantable insulin pump system.
License Property
Implantable microinfusion pump systems intended for in vivo use; utilizes Pump Technology for diabetes or non-diabetes applications. Glucose Controllers, Glucose Monitors, Long-Term Glucose Sensors and the abdominal lead that connects the implantable pump to a Long-Term Glucose Sensor are not Licensed Products.  An apparatus or system which utilizes Glucose Sensing Technology to control an insulin infusion device in a human or in an animal.   Any monitor product utilizing Glucose Sensing Technology to provide indications of glucose concentration or changes in glucose concentration in a human or in an animal.

IPSCIO Record ID: 29433

License Grant
As part of a strategic partnership, technology for a small device that sticks to the body and injects a dose of insulin was transferred for commercialization.  Licensee will acquire a majority interest in Licensor's subsidiary.
License Property
The Licensor is a privately held business who has been developing the h-Patch as a simple, unobtrusive tool to help people with type 2 diabetes control their injections of insulin.

The h-Patch is a small, flat plastic pod with a sticky side that adheres to a patient's skin. A tiny micro-needle in the device injects insulin into the patient's skin when the patient hits a start button. When the device has emptied all its insulin, the needle retracts and the entire device is discarded.

Field of Use
The Licensee is an investment company that is also taking a major ownership interest in the Licensor.

IPSCIO Record ID: 266845

License Grant
For the Exclusive License,  the Swiss Licensor grants an exclusive right and license or sublicense, as applicable, in the Territory, with the right to grant sublicenses, under the Licensor Technology and Licensor Technology Improvements to make and have made, to use and have used, to develop and have developed, to sell and have sold, to offer for sale and have offered for sale, to import and export and have imported and exported Licensed Products in the Exclusive Field in the Territory during the Term.

For the Non-Exclusive, Research License, Licensor grants a nonexclusive, research only license or sublicense, as applicable, in the Territory, with the right to grant sublicenses, under the Licensor Technology and Licensor Technology Improvements to conduct non-human studies for the development of Other Products, solely for the prevention or treatment of a Target Indication in the Target Populations.

License Property
Licensors technology is relating to the aerosolization of liquid forms of drug products and the Aerosol Devices and Disposable Dose Packs.

Licensed Product means a combination drug-device product using or otherwise practicing the Licensor Technology and delivering Pulmonary Surfactants (alone or in combination with other pharmaceutical compounds).

Drug Product means a pharmacological agent(s), including Pulmonary Surfactants, together with any excipients or inactive ingredients, formulated for use in connection with an Aerosol Device or Disposable Dose Packet.

Aerosol Device means a device to aerosolize a pharmaceutical compound for administration to humans. It is contemplated that the Aerosol Device shall consist of permanent (e.g., nondisposable) components that control power and electronics (e.g., control unit) and a physical mechanism (e.g., pump) to provide a means for dispensing the Drug Product from the container closure system.

Aerosol Technology means any technology related to the aerosolization of a liquid form of a pharmaceutical compound. Aerosol Technology does not include technology that is related to the delivery of aerosols as dry powders.

An Other Product means a combination drug-device product using or otherwise practicing the Licensor Technology and delivering pharmaceutical compounds other than Pulmonary Surfactants as an active ingredient in humans, alone or in combination with other pharmaceutical compounds, that are other than Pulmonary Surfactants.

Field of Use
Exclusive Field means the therapeutic or preventative use in humans of Aerosol Technology to deliver Pulmonary Surfactants (alone or in combination with any other pharmaceutical compound(s)) as an active ingredient for the prevention or treatment of Respiratory Indications.

Target Indications means the following Respiratory Indications Respiratory Distress Syndrome (RDS); Chronic Lung Disease (BPD); Transient Tachypnea; Hypoxemia; Pulmonary Hypertension; Pneumonia; Bronchiolitis; Diaphragmatic Hernia; Acute Lung Injury (ALI); Acute Respiratory Distress Syndrome (ARDS); Lung Transplantation; Respiratory Syncitial Virus (RSV); Cystic Fibrosis; Chronic Obstructive Pulmonary Disease (COPD); and Emphysema.

Target Populations means human patients in a Hospital Setting receiving forms of treatment for the applicable Respiratory Indication that are typically and principally provided within a Hospital Setting.

The restructure strategic alliance agreement is to unite two complementary respiratory technologies – Licensee peptide-containing synthetic surfactant technology with Licensor’ novel capillary aerosolization technology – to deliver therapeutics to the deep lung.

IPSCIO Record ID: 28235

License Grant
The Amendment expands the scope of the Licensee's license from the Licensor. Under the Cross-License Amendment, the Licensee will continue to develop the pulse program in the field of cardiopulmonary disease.
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices.

INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.

The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.

Field of Use
The Licensee will develop its Licensor pulse program for the treatment of three additional cardiopulmonary diseases chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness.

IPSCIO Record ID: 233472

License Grant
Licensor grants an exclusive, including with respect to Licensor except as necessary for Licensor to carry out its obligations under this Agreement, license, with the right to sublicense, in the Territory, under the Licensors Intellectual Property, to develop, make or have made, use, offer for sale, sell, import, market and promote Product.
License Property
The proprietary device is AZ-003 or Staccato® fentanyl, a multiple-dose delivery system for fentanyl that permits rapid systemic delivery of fentanyl through inhalation, and Licensor has initiated clinical studies with respect to AZ-003.

The patents relate to Delivery of Opioids through an Inhalation Route.

The technology, the Staccato system, vaporizes excipient-free drugs to form condensation aerosols that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience.

Field of Use
This product AZ-003 (Staccato fentanyl) is being developed for for the treatment of breakthrough pain in cancer and non-cancer patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.